Biotech Values

[DewDiligence]

GILD, JNJ close the deal to collaborate on Prezista-based all-in-one HIV pill:

http://finance.yahoo.com/news/Gilead-Sciences-Finalizes-bw-2357363404.html?x=0&l=1

This deal was announced in June (#msg-64697419) but did not become official until today. (I wonder what took so long.)

The four drugs in the combo pill are Prezista (JNJ’s PI), Cobicistat (GILD’s PK booster), Emtriva (one of the two nukes in Truvada), and GS7340, a prodrug of tenofovir in phase-1b that is similar to Viread (#msg-62301844).

Prezista-based cocktails have an 8% share of the US market, according to GILD’s 2Q11 CC (#msg-65585689). Inasmuch as an HIV therapy is taken forever (as long as it keeps working), having a single pill ought to boost the market share to a meaningful degree.